Moleculin Releases Preliminary MIRACLE Trial Data for Annamycin in Relapsed or Refractory AML

Preliminary unblinded efficacy data from the first 45 patients in Moleculin Biotech's pivotal Phase 2/3 MIRACLE trial are now in circulation, and for drug development and manufacturing planning teams tracking the R/R AML space, the early signals carry operational weight well ahead of any approval decision. The data cover Part A of the adaptive, double-blind, placebo-controlled study evaluating Annamycin in combination with cytarabine (the AnnAraC regimen) in relapsed or refractory acute myeloid leukemia.

Chairman and CEO Walter Klemp addressed the preliminary findings in a virtual investor segment released on 6 July 2026, summarising efficacy trends observed across both Annamycin treatment arms and referencing recent market research on the potential addressable market if the compound reaches approval. Annamycin, also designated naxtarubicin, is an anthracycline engineered to circumvent multidrug resistance mechanisms and to avoid the cardiotoxicity profile associated with currently prescribed anthracyclines in this class.

The MIRACLE trial (MB-108) is a multi-centre, randomised, adaptive design study initiated following a Phase 1B/2 programme (MB-106) conducted with FDA input that Moleculin characterises as substantially de-risking the development pathway. The company notes the programme remains subject to future regulatory filings and potential additional FDA feedback, as well as review by foreign equivalents. Moleculin has also disclosed that significant additional financing, for which no commitments currently exist, will be required to advance the trial to completion.

For process development and CMC teams, the relevance at this stage centres on the interim nature of the dataset. The n=45 cohort has not achieved statistical significance, and the company's own forward-looking disclosures caution that early efficacy trends in a limited population may not be predictive of results from the completed study. Scale-up planning and technology transfer decisions tied to Annamycin's anthracycline chemistry would appropriately remain contingent on Part B data and any subsequent regulatory interactions.

Moleculin's broader pipeline includes WP1066, a p-STAT3 inhibitor targeting brain and pancreatic tumours, and WP1122, an antimetabolite in development for pathogenic viruses and certain oncology indications, though neither programme is at a stage that would currently drive near-term manufacturing commitments.

The next measurable checkpoint for the MIRACLE programme is the accumulation of sufficient patient data in the full study population to support a statistically powered efficacy read-out.

Source: Moleculin Biotech, Inc. via GlobeNewswire, 6 July 2026.